Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
FGPR$20.21+0.01(+0.05%)Ferrellgas and Operation Warm to Give More Than 350 Flagstaff Children New Winter Coats[9:30:00 AM ET]FGPR$20.21+0.01(+0.05%)Ferrellgas and Operation Warm to Give 350 Bay City Children New Winter Coats[9:30:00 AM ET]APH$80.00+1.79(+2.29%)Industrial Growth Partners Announces Sale of AdvancedPCB Industrial Growth Partners ("IGP") is pleased to announce that it has entered into a definitive agreement to sell AdvancedPCB Holdings, LLC...[9:27:00 AM ET]BLGO$0.07-0.00(-3.62%)BioLargo Introduces barebird, a Company-Owned Brand, Reuniting Key Teams Behind Pooph's Consumer Market Success[9:25:00 AM ET]TWOSF$0.24-0.00(-0.04%)T2 Metals to Attend the 52nd Annual New Orleans Investment Conference[9:25:00 AM ET]MOB$3.32+0.03(+0.91%)Mobilicom to Showcase Cybersecure Portfolio Highlighting Newly Launched SwarmiX at ARC WEPTAC Conference[9:22:00 AM ET]COSM$0.25+0.02(+6.82%)Noble Capital Markets Initiates Equity Research Coverage on Cosmos Health with Outperform Rating and $1.40 Price Target[9:20:00 AM ET]MGN$2.83-0.23(-7.52%)Megan Holdings Limited Announces Pricing of Up to $7.5 Million Follow-on Public Offering[9:20:00 AM ET]ADSE$9.36+0.06(+0.65%)ADS-TEC Energy Advances One of Europe's Largest Battery Storage Projects as Building Permit Nears[9:18:00 AM ET]ELS$58.45-1.04(-1.75%)ELS Declares Fourth Quarter 2026 Dividend On October 27, 2026, the Board of Directors of Equity LifeStyle Properties, Inc. (NYSE: ELS) (referred to herein as "we," "us," and "our") declared a ...[9:18:00 AM ET]IREN$27.27-0.18(-0.64%)IREN and Wingspire Equipment Finance Complete $363 Million Financing for High-Density AI Compute Assets[9:17:00 AM ET]GSAT$83.91+0.01(+0.01%)XCOM RAN Wins the Gold Stevie® 2026 Award for Technology Excellence[9:16:00 AM ET]CYAB$0.13-0.00(-0.53%)Cyabra Finds Coordinated Inauthentic Activity in Five of Six Competitive Midterm Races, Affecting Candidates from Both Parties[9:15:00 AM ET]AIBT$0.000.00(0.00%)AIBotics Provides PHILL ROBOT™ Manufacturing Update as 3DX Industries Supports Five-Unit Pilot[9:15:00 AM ET]LGVN$1.79+0.06(+3.42%)Longeveron Announces Engagement of Lucid Capital Markets[9:15:00 AM ET]QNC$1.10+0.01(+0.92%)Quantum eMotion to Showcase Quantum-Safe Cybersecurity Portfolio at World Quantum Cannes Festival November 17-18, 2026[9:15:00 AM ET]

MTVA · NASDAQ

MetaVia Inc.

$1.18 +0.02 (+1.37%)

Company overview

MetaVia Inc., a clinical-stage biotechnology company, focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), and has completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus (T2DM); and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in preclinical development for the treatment of obesity.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$7.8M
Employees
9
Headquarters
Cambridge, MA
Website
metaviatx.com
CEO
Hyung Heon Kim
Listed
August 5, 2016
P/E
-0.19
Dividend yield
0.00%

Company financials

Revenue
$0.00
Gross profit
-$15,000
Operating income
-$13.8M
EBITDA
-$13.5M
Net income
-$13.1M
EPS
-$6.03
Total assets
$14.4M
Total debt
$194,000
Earnings yield
-515.38%

Price chart

0.831.742.643.544.44
MTVA 1D NASDAQ O1.27H1.27L1.15C1.16-0.05 (-4.19%)Vol9.25K

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
Ticker Type Headline Source Published
MTVAMetaVia Inc. Press release MetaVia to Present Phase 1 Clinical Trial Data for DA-1726 in Oral Presentation at the Precision Liver Symposium 2026 MetaVia Inc. PR Newswire
MTVAMetaVia Inc. Press release MetaVia Appoints Seasoned Clinical Development Executive Sarah Browne, M.D., as Chief Medical Officer MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced the… PR Newswire
MTVAMetaVia Inc. Press release MetaVia Announces Preclinical Findings Supporting Biological Rationale for DA-1726's Waist Circumference Reduction PR Newswire
MTVAMetaVia Inc. Press release MetaVia Reports Second Quarter 2026 Financial Results and Provides Corporate Update PRNewsWire
MTVAMetaVia Inc. Stock news Why MetaVia Stock Is Surging On Friday? Benzinga
MTVAMetaVia Inc. Stock news Why MetaVia Stock Is Falling On Thursday? Benzinga
MTVAMetaVia Inc. Press release MetaVia Highlights Peer-Reviewed Publication Supporting the Anti-Fibrotic Potential of Vanoglipel in MASH PRNewsWire
MTVAMetaVia Inc. Press release MetaVia Reports First Quarter 2026 Financial Results and Provides Corporate Update PRNewsWire
MTVAMetaVia Inc. Press release MetaVia to Present Data Highlighting DA-1726, a GLP-1/Glucagon Dual Agonist, in a Late-Breaking Poster Presentation at the EASL Congress 2026 PRNewsWire
MTVAMetaVia Inc. Press release MetaVia Doses the First Patient in Higher-Dose Phase 1 Study of DA-1726, Its GLP-1 and Glucagon Dual Agonist for the Treatment of Obesity PRNewsWire
MTVAMetaVia Inc. Press release MetaVia Reports Year End 2025 Financial Results and Provides Corporate Update PRNewsWire
MTVAMetaVia Inc. Press release MetaVia Advances GLP-1-Based Obesity Program with IRB Approval for Higher-Dose Phase 1 Studies of DA-1726, a GLP-1 and Glucagon Dual Agonist Demonstrating Best-in-Class Potential for Weight Loss and Glucose Control PRNewsWire
MTVAMetaVia Inc. Stock news MetaVia Inc. (NASDAQ:MTVA) Short Interest Up 82.9% in February Defense World
MTVAMetaVia Inc. Press release MetaVia Expands Global Patent Protection for Vanoglipel, Supporting Metabolic and Liver Disease Therapy Through 2035 PRNewsWire
MTVAMetaVia Inc. Press release MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Life Sciences Virtual Investor Forum PRNewsWire
MTVAMetaVia Inc. Press release MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Emerging Growth Conference PRNewsWire
MTVAMetaVia Inc. Stock news MetaVia Secures Dozens Of Patents Through 2041 For Obesity Drug Benzinga
MTVAMetaVia Inc. Press release MetaVia Builds Comprehensive Global Patent Protection for DA-1726, Securing Exclusive Rights to Novel Obesity and Metabolic Therapy Through 2041 PRNewsWire
MTVAMetaVia Inc. Press release MetaVia Announces Positive AI-Modeling Results from its Ongoing Syntekabio Collaboration, Confirming Key Therapeutic Targets for Vanoglipel PRNewsWire
MTVAMetaVia Inc. Press release MetaVia Announces the Closing of $9.3 Million Underwritten Public Offering, Including Full Exercise of Allotment Option PRNewsWire
See more
FAQ

Questions about MetaVia Inc.

What does MetaVia Inc. do?
MetaVia Inc., a clinical-stage biotechnology company, focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), and has completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus (T2DM); and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in preclinical development for the treatment of obesity.
What is MTVA's market cap?
MetaVia Inc. (MTVA) is a listed stock with a live quote. The latest market cap on this page is $7.8M.
Where is MetaVia Inc. headquartered?
MetaVia Inc. is headquartered in Cambridge, MA.
How do I get MTVA news from the API?
Call GET /v1/news?tickers=MTVA. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search the full archive in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees the full archive.
How far back does MTVA news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for MTVA, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees the full archive as headlines are ingested. A Free API key returns the last year. Pro keys search the full archive.
Is the MTVA price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 1,000 REST requests a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs